Characterization of mpox
Active Awarded Last action
- Contract number
- 75N91025F00017
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,583,900
Award facts
- Contract value 100% obligated
- $5,583,900.00 Current and potential, with all options
- Completion date 71% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $5,583,900 |
About this award
The National Institute of Allergy and Infectious Diseases issued a delivery order to Leidos Biomedical Research Inc. on September 29, 2025, with a ceiling value of $5.583 million for characterization of mpox, issued under a cost-plus-fixed-fee pricing structure.
Place of performance is Frederick, Maryland. Ultimate completion is March 28, 2027. Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research on behalf of the National Cancer Institute and delivers biomedical research and facilities support services across the NIH ecosystem as an FFRDC contractor. The company maintains a workforce of approximately 1,830 FTEs and engages subcontractors for specialized research activities including molecular diagnostics, laboratory automation, bioprocess systems, and academic partnerships.
Quick answers
Who was awarded contract 75N91025F00017?
75N91025F00017 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 29, 2025.
How much is contract 75N91025F00017 worth?
The government has obligated $5,583,900 on 75N91025F00017.
Which agency awarded contract 75N91025F00017?
National Cancer Institute (National Institutes of Health) awarded 75N91025F00017, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91025F00017 an order under another contract?
Yes. 75N91025F00017 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00017 competed?
The extent of competition for 75N91025F00017 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award